32570-90-4

Usage

Molecular Structure

2,5-Dimethyl-1-pyridin-2-yl-1H-pyrrole-3-carbaldehyde has a complex molecular structure, featuring a combination of aromatic heterocycles and functional groups.

Aromatic Heterocycles

The compound contains two aromatic heterocycles, a pyridinyl group and a pyrrole ring, which contribute to its stability and chemical properties.

Pyridinyl Group

A six-membered nitrogen-containing ring, which is part of the compound's structure, providing a source of nitrogen for potential reactions and interactions.

Pyrrole Ring

A five-membered nitrogen-containing ring, which is part of the compound's structure, offering a different electronic environment compared to the pyridinyl group.

2,5-Dimethyl Substitution

The compound has two methyl groups attached to the 2nd and 5th positions of the pyridinyl ring, which can influence its reactivity, polarity, and solubility.

Carbaldehyde Functional Group

A carbonyl group (C=O) bonded to a hydrogen atom, which is present in the compound, providing a site for various chemical reactions and potential applications in organic synthesis.

Applications

Due to its unique structure and reactivity, 2,5-dimethyl-1-pyridin-2-yl-1H-pyrrole-3-carbaldehyde may have potential applications in organic synthesis, pharmaceuticals, and related fields.

Further Research

Additional studies and testing are required to determine the specific uses, potential effects, and full scope of applications for this chemical compound.

Upstream product

• 504-29-0 2-aminopyridine 
• 32570-88-0 2-(2,5-dimethyl-1H-pyrrol-1-yl)pyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 110-13-4 2,5-hexanedione 

Relevant academic research and scientific papers

Easy-To-Synthesize Spirocyclic Compounds Possess Remarkable in Vivo Activity against Mycobacterium tuberculosis

Society urgently needs new, effective medicines for the treatment of tuberculosis. To kick-start the required hit-to-lead campaigns, the libraries of pharmaceutical companies have recently been evaluated for starting points. The GlaxoSmithKline (GSK) library yielded many high-quality hits, and the associated data were placed in the public domain to stimulate engagement by the wider community. One such series, the spiro compounds, are described here. The compounds were explored by a combination of traditional in-house research and open source methods. The series benefits from a particularly simple structure and a short associated synthetic chemistry route. Many members of the series displayed striking potency and low toxicity, and highly promising in vivo activity in a mouse model was confirmed with one of the analogues. Ultimately the series was discontinued due to concerns over safety, but the associated data remain public domain, empowering others to resume the series if the perceived deficiencies can be overcome.

Discovery, synthesis and SAR analysis of novel selective small molecule S1P4-R agonists based on a (2Z,5Z)-5-((pyrrol-3-yl)methylene)-3- alkyl-2-(alkylimino)thiazolidin-4-one chemotype

High affinity and selective S1P4 receptor (S1P4-R) small molecule agonists may be important proof-of-principle tools used to clarify the receptor biological function and effects to assess the therapeutic potential of the S1P4-R in diverse disease areas including treatment of viral infections and thrombocytopenia. A high-throughput screening campaign of the Molecular Libraries-Small Molecule Repository was carried out by our laboratories and identified (2Z,5Z)-5-((1-(2-fluorophenyl)-2,5-dimethyl-1H- pyrrol-3-yl)methylene)-3-methyl-2-(methylimino) thiazolidin-4-one as a promising S1P4-R agonist hit distinct from literature S1P4-R modulators. Rational chemical modifications of the hit allowed the identification of a promising lead molecule with low nanomolar S1P4-R agonist activity and exquisite selectivity over the other S1P 1-3,5-Rs family members. The lead molecule herein disclosed constitutes a valuable pharmacological tool to explore the effects of the S1P4-R signaling cascade and elucidate the molecular basis of the receptor function.